SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings beat expectations, with traders highlighting rapid growth in its AI-computing business and Starlink. Bulls celebrated the results and ambitious growth outlook, while skeptics questioned the valuation and heavy infrastructure spending and noted the stocks muted reaction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results were broadly solid, but softer forward guidanceincluding a reduced advertising outlook and lower expected cash flowhas driven a sharp post-earnings selloff amid concerns about slowing growth. Traders are split between expecting further downside and viewing the drop as an overreaction to guidance despite the earnings beat.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue outlook and projected higher gross margins, citing AI-platform demand. Traders largely welcomed the surprise as evidence of strong AI-server demand and a possible boost to the broader AI trade, while others questioned whether the gains would hold amid persistent concerns about management, execution, and volatile price action.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of large Chinese orders for Nvidias export-compliant RTX PRO 5500 GPUs are fueling discussion, with traders pointing to strong demand but noting supply constraints and uncertainty over how much Nvidia can deliver. The stocks muted response has frustrated bulls, while others remain cautious amid broader concerns about AI spending, financing risks and recent weakness in chip stocks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th death event that triggers final analysis of its Phase 3 REGAL trial of GPS; the last disclosed count was 78, and the event has not been confirmed in the discussion. The CEOs next chapter remarks have also fueled speculative buyout talk, while others caution that the sharp price moves have occurred without new clinical results.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its Q3 earnings report, with traders weighing the recent rebound against concerns about margins and whether results or guidance can justify high expectations. Speculative SpaceX merger chatter adds to the discussion, while views remain split between a continued rally and a post-earnings pullback.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is in focus after a strong Q3 earnings beat was met with a sharp selloff, as traders weighed a proposed antitrust settlement and a narrower full-year da Vinci procedure-growth outlook. Some see the reaction as excessive given continued business growth, while others view the outlook and settlement as reasons for caution.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels volatile rebound after a sharp semiconductor selloff has drawn attention to JPMorgans upgrade to Neutral and the companys turnaround prospects. Bulls point to potential foundry wins and improving execution, while skeptics question the valuation and durability of the bounce; earnings are also in focus.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept up in a sharp selloff across AI infrastructure and neocloud stocks, as traders worry that heavy data-center spending, debt and financing costs may outpace returns; CoreWeaves debt concerns and Gartners warning about neocloud consolidation add to the pressure. Bulls argue Nebius has stronger finances and can benefit from sustained demand for AI compute, while bears question whether the buildout can be funded profitably; traders are also watching upcoming earnings and hyperscaler capex commentary.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention after a small-cap rebound amid rotation away from tech, with traders pointing to easing yields and reports of a possible U.S.Iran deal that helped lift broader markets. The deal remains unconfirmed, and the community is split between seeing a relief rally and viewing the move as a fragile, headline-driven bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingPR NewswireWESTPORT, Conn., Oct...

Atrium Therapeutics Announces $50 Million Private Placement

Atrium Therapeutics Announces $50 Million Private Placement Atrium Therapeutics Announces $50 Million Private PlacementPR NewswireSAN DIEGO, Oct. 8, 2026SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing...

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Sept. 21, 2026 SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...

Atrium Therapeutics to Participate in Upcoming Investor Conferences

Atrium Therapeutics to Participate in Upcoming Investor Conferences Atrium Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), abiopharmaceutical company advancing...

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Aug. 20, 2026 SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Atrium Therapeutics Reports Second Quarter 2026 Financial Results Atrium Therapeutics Reports Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2026 -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment...

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PR Newswire SAN DIEGO, Aug. 13, 2026 SAN DIEGO...

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, July 20, 2026 SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome PR Newswire SAN DIEGO, July 14, 2026...

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, June 23, 2026 SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

Atrium Therapeutics Inc.

Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.</li><li>Intellia Therapeutics declined by more than 44% after the company announced a temporary pause in patient dosing and screening for two of its late-stage trials.</li><li>Avidity Biosciences shares were up nearly 42% in Monday’s midday trade after Novartis AG (NVS) agreed to acquire the former for $12 billion.</li></ul>U.S. equities surged in Monday’s midday trade after trade tensions with China cooled down after officials of the two countries met over the weekend.President Donald Trump expressed optimism about striking a deal with China. “I've got a lot of respect for President Xi, and I think we're going to come away with a deal. We have China coming and its going to be very interesting,” he told reporters aboard Air Force One, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/asia-pacific/trump-says-he-might-sign-final-tiktok-deal-thursday-2025-10-27/">report</a> by Reuters.President Trump is scheduled to meet his Chinese counterpart, President Xi Jinping, on Thursday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.94% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, rose 1.56%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, gained 0.42%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s midday trade:</h2><a href="https://stocktwits.com/symbol/QCOM">Qualcomm Inc. (QCOM)</a>Qualcomm shares were up more than 11% in Monday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qcom-stock-jumps-after-company-launches-ai-chips-to-take-on-amd-nvidia/cLG0OGnR3M6">unveiled</a> two artificial intelligence (AI) accelerator chips, the AI200 and AI250, aimed at enterprise and cloud customers.<a href="https://stocktwits.com/symbol/QCOM">QCOM stock</a> is up 22% year-to-date.<a href="https://stocktwits.com/symbol/TSLA">Tesla Inc. (TSLA)</a>Tesla shares gained nearly 6% in Monday’s midday trade. Cantor Fitzgerald hiked its price target on the stock to $510 from $355, while maintaining an ‘Overweight’ rating, according to TheFly. The firm cited better-than-expected third-quarter (Q3) revenue, gross margin, and free cash flow.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is up 14% year to date.<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics Inc. (NTLA)</a>Intellia Therapeutics declined over 44% in Monday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-ntla-stock-slump-pre-market-today/cLG07OdR3Ms">announced</a> a temporary pause in patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.<a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> is up 24% year to date.<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences Inc. (RNA)</a>Avidity Biosciences shares were up nearly 42% in Monday’s midday trade after Novartis AG (NVS) agreed to acquire the former for $12 billion. The deal offers Avidity investors $72 per share, a 46% premium over the stock’s Friday closing price.<a href="https://stocktwits.com/symbol/RNA">RNA stock</a> is up 141% year to date.<a href="https://stocktwits.com/symbol/DYN">Dyne Therapeutics Inc. (DYN)</a>Dyne Therapeutics shares were up 41% in Monday’s midday session following the acquisition of Avidity by Novartis. Analysts at Morgan Stanley&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">stated</a> that the Avidity acquisition provides positive read-through to Dyne, as reported by TheFly. Both Avidity and Dyne are advancing therapies for rare muscle diseases, myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.<a href="https://stocktwits.com/symbol/DYN">DYN stock</a> is up 3% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-hits-all-time-high-market-capitalization-inches-toward-4-trillion/cLG0gUVR3u9">Apple Stock Hits All-Time High, Market Capitalization Inches Toward $4 Trillion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.

Intellia Therapeutics Inc

Qualcomm, Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.98
Prev Close	$7.61
Open	$7.75
Dividend Yield	N/A
50-Day Moving Average	$10.59
Beta	0.76
Avg. Volume	418,728.24
PE Ratio	N/A

52-Week High	$16.77
52-Week Low	$7.49
Market Capitalization	$169.52M
EPS (Annual)	-$2.89
Price to Book	0.61
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

RNA Fundamentals